Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

被引：2

作者：

Zhou, Bin ^{[1
,2
]}

Wang, Beilei ^{[1
,3
,4
]}

Zou, Fengming ^{[1
,3
,4
]}

Mei, Husheng ^{[1
,2
]}

Liu, Qingwang ^{[1
,3
,4
]}

Qi, Shuang ^{[1
,3
,4
,5
]}

Wang, Wenliang ^{[1
,5
]}

Jin, Rui ^{[1
,3
]}

Wang, Aoli ^{[1
,3
,4
]}

Chen, Yongfei ^{[1
,3
,4
]}

Liu, Feiyang ^{[1
,4
,5
]}

Wang, Wenchao ^{[1
,2
,3
,4
,5
]}

Liu, Jing ^{[1
,2
,3
,4
,5
,6
]}

Liu, Qingsong ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei 230031, Anhui, Peoples R China

[2] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China

[3] Chinese Acad Sci, Hefei Canc Hosp, Hefei 230031, Anhui, Peoples R China

[4] Precis Med Res Lab Anhui Prov, Hefei 230088, Anhui, Peoples R China

[5] Primary Cell Engn Joint Lab Anhui Prov, Hefei 230088, Anhui, Peoples R China

[6] Chinese Acad Sci, Hefei Inst Phys Sci, Hefei 230031, Anhui, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 261卷

基金：

中国国家自然科学基金;

关键词：

Enhancer of zeste homolog 2; Covalent inhibitor; EZH2; degrader; HISTONE METHYLTRANSFERASE EZH2; LYSINE; 27; POLYCOMB; INHIBITOR; LYMPHOMA; COMPLEX; DESIGN; HYPERTRIMETHYLATION; IDENTIFICATION; METHYLATION;

D O I：

10.1016/j.ejmech.2023.115825

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

EZH2 is overexpressed in multiple types of cancer and high expression level of EZH2 correlates with poor prognosis. Besides the regulation of H3K27 trimethylation, EZH2 itself regulates its downstream proteins in a PRC2-and methylation-independent way. Starting from an approved EZH2 inhibitor EPZ-6438, we used covalent drug design and medicinal chemistry approaches to discover a novel covalent EZH2 degrader 38, which forms a covalent bond with EZH2 Cys663 and showed strong biochemical activities against EZH2 WT and mutants. Compound 38 exhibited potent antiproliferation effects against both B-cell lymphoma and TNBC cell lines by reducing the levels of H3K27me3 and EZH2. The mass spectrometry, washout and competition experiments confirmed the covalent binding of 38 to EZH2. This study demonstrates that covalent EZH2 degraders could provide an opportunity for the development of promising new drug candidates.

引用

页数：23

共 50 条

[21] An Evolutionarily Conserved Structural Platform for PRC2 Inhibition by a Class of Ezh2 Inhibitors
Bratkowski, Matthew
Yang, Xin
Liu, Xin
SCIENTIFIC REPORTS, 2018, 8
[22] Targeting EZH2 in cancer therapy
Yamagishi, Makoto
Uchimaru, Kaoru
CURRENT OPINION IN ONCOLOGY, 2017, 29 (05) : 375 - 381
[23] EZH2: An Accomplice of Gastric Cancer
Yu, Wuhan
Liu, Ning
Song, Xiaogang
Chen, Lang
Wang, Mancai
Xiao, Guohui
Li, Tengfei
Wang, Zheyuan
Zhang, Youcheng
CANCERS, 2023, 15 (02)
[24] The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration
Bae, Woo Kyun
Kang, Keunsoo
Yu, Ji Hoon
Yoo, Kyung Hyun
Factor, Valentina M.
Kaji, Kosuke
Matter, Matthias
Thorgeirsson, Snorri
Hennighausen, Lothar
FASEB JOURNAL, 2015, 29 (05) : 1653 - 1662
[25] Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies
Mei, Husheng
Wu, Hong
Yang, Jing
Zhou, Bin
Wang, Aoli
Hu, Chen
Qi, Shuang
Jiang, Zongru
Zou, Fengming
Wang, Beilei
Liu, Feiyang
Chen, Yongfei
Wang, Wenchao
Liu, Jing
Liu, Qingsong
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
[26] EZH2: biology, disease, and structure-based drug discovery
Tan, Jin-zhi
Yan, Yan
Wang, Xiao-xi
Jiang, Yi
Xu, H. Eric
ACTA PHARMACOLOGICA SINICA, 2014, 35 (02) : 161 - 174
[27] Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer
Verma, Sharad K.
Knight, Steven D.
FUTURE MEDICINAL CHEMISTRY, 2013, 5 (14) : 1661 - 1670
[28] A patent review of EZH2 inhibitors from 2017 and beyond
Wan, Guoquan
Feng, Huan
Su, Chang
Zhu, Yongxia
Zhang, Lidan
Zhang, Qiangsheng
Yu, Luoting
EXPERT OPINION ON THERAPEUTIC PATENTS, 2023, 33 (04) : 293 - 308
[29] Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression
Grzenda, Adrienne
Lomberk, Gwen
Svingen, Phyllis
Mathison, Angela
Calvo, Ezequiel
Iovanna, Juan
Xiong, Yuning
Faubion, William
Urrutia, Raul
EPIGENETICS & CHROMATIN, 2013, 6
[30] A687V EZH2 is a gain-of-function mutation found in lymphoma patients
Majer, Christina R.
Jin, Lei
Scott, Margaret Porter
Knutson, Sarah K.
Kuntz, Kevin W.
Keilhack, Heike
Smith, Jesse J.
Moyer, Mikel P.
Richon, Victoria M.
Copeland, Robert A.
Wigle, Tim J.
FEBS LETTERS, 2012, 586 (19) : 3448 - 3451

← 1 2 3 4 5 →